Press Releases

2016.12.08 Local (JPN) PDF (415KB)
Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary
2016.12.06 R&D PDF (194KB)
Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology
2016.12.02 R&D PDF (181KB)
U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer
2016.11.30 R&D PDF (115KB)
Daiichi Sankyo Announces Japanese Research Partners Selected for 2016 TaNeDS Collaborative Drug Discovery Project
2016.10.26 Corporate PDF (109KB)
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond™ Formulated with SentryBond™ Abuse-Deterrent Technology
2016.10.25 R&D PDF (44KB)
Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
2016.10.25 Corporate PDF (66KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares and Completion of Acquisition
2016.10.21 R&D PDF (96KB)
Daiichi Sankyo Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease
2016.10.21 R&D PDF (162KB)
ENLIVEN Phase 3 Study of Pexidartinib in Tenosynovial Giant Cell Tumor (TGCT) Will Continue to Completion Following Enrollment Discontinuation
2016.10.12 Corporate PDF (34KB)
Daiichi Sankyo and Dana-Farber Cancer Institute Announce Lung Cancer Research Collaboration
2016.10.12 R&D PDF (46KB)
Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia
2016.10.12 R&D PDF (106KB)
Daiichi Sankyo Announces TaNeDS Europe 2017 Collaborative Drug Discovery Programme
2016.10.11 R&D PDF (198KB)
Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress
2016.10.05 Corporate PDF (30KB)
Daiichi Sankyo Moves Forward with Innovative Antimalarial Drug Research Collaboration
2016.10.04 Corporate PDF (251KB)
Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx
2016.10.03 R&D PDF (102KB)
Daiichi Sankyo Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly
2016.10.03 Corporate PDF (96KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2016.09.28 Corporate PDF (198KB)
Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration
2016.09.28 R&D PDF (160KB)
Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer
2016.09.27 R&D PDF (131KB)
Daiichi Sankyo Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid Receptor Antagonist for Treatment of Essential Hypertension
2016.09.23 Products PDF (112KB)
Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab
2016.09.14 CSR PDF (109KB)
Daiichi Sankyo Selected for Dow Jones Sustainability Asia Pacific Indices for Seventh Consecutive Year
2016.09.01 Corporate PDF (96KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2016.08.31 Products PDF (141KB)
Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been launched.
2016.08.30 R&D PDF (271KB)
ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo’s Once-Daily LIXIANA® in Patients with Atrial Fibrillation Undergoing Cardioversion
2016.08.26 Corporate PDF (97KB)
Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir® Dry Powder Inhaler 20mg
2016.08.26 Products PDF (136KB)
Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan
2016.08.24 R&D PDF (126KB)
Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
2016.08.01 Corporate PDF (95KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2016.07.15 Corporate PDF (115KB)
Daiichi Sankyo Issues Unsecured Straight Bonds
2016.07.14 Corporate PDF (152KB)
Amgen and Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
2016.07.05 Corporate PDF (91KB)
Daiichi Sankyo Announces Details of Executive Share Options
2016.07.04 Products PDF (294KB)
UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT®) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy
2016.07.01 CSR PDF (103KB)
14th Takamine Memorial Daiichi Sankyo Prize Winner Announced
2016.07.01 Corporate PDF (95KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2016.06.30 CSR PDF (85KB)
FTSE Russell Corporation Selects Daiichi Sankyo for FTSE4Good Global Index
2016.06.27 Corporate PDF (242KB)
Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban
2016.06.23 CSR PDF (148KB)
Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 9th Annual Clinical Pharmacology Research Award
2016.06.20 Corporate PDF (65KB)
Daiichi Sankyo Announces Determination of Matters Relating to Acquisition of Own Shares
2016.06.20 Corporate PDF (173KB)
Daiichi Sankyo to Issue Share Options as Remuneration
2016.06.16 Local (JPN) PDF (310KB)
Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary
2016.06.14 Products PDF (387KB)
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108
2016.05.31 R&D PDF (157KB)
Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
2016.05.25 Products PDF (113KB)
Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg
2016.05.23 Corporate PDF (153KB)
Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults
2016.05.12 Corporate PDF (149KB)
Daiichi Sankyo Announces Changes to Representative Director and Members of the Board
2016.05.12 Corporate PDF (213KB)
Differences Between Consolidated Results for Fiscal 2015 and Fiscal 2014
2016.05.10 Corporate PDF (15KB)
Daiichi Sankyo Signs License Agreement with Cell Therapy Ltd. for Heartcel(TM)
2016.05.06 Corporate PDF (113KB)
The outcome of arbitration proceeding with certain former shareholders of Ranbaxy
2016.04.18 CSR PDF (95KB)
Daiichi Sankyo Offers Assistance to Victims of the 2016 Kumamoto Earthquake
2016.04.05 R&D PDF (33KB)
Open innovation research on new stem cells by Asahikawa Medical University, Daiichi Sankyo, and Mitsubishi UFJ Capital
2016.04.05 Corporate PDF (108KB)
Daiichi Sankyo Enters Into Clinical Collaboration Agreement in Japan for Anticoagulant Reversal Agent Andexanet Alfa
2016.03.31 Products PDF (26KB)
Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride
2016.03.31 Corporate PDF (65KB)
Daiichi Sankyo Announces Closure of Daiichi Sankyo Chemical Pharma Hiratsuka Plant
2016.03.31 Corporate PDF (3.68MB)
Daiichi Sankyo Announces 5-year Business Plan (FY 2016 - FY 2020)
2016.03.30 R&D PDF (17KB)
Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment
2016.03.22 R&D PDF (188KB)
Commencement of First-in-Human Clinical Trial for New Molecular Targeting Drug, Co-Developed with The University of Tokyo and National Cancer Center, to Treat Malignant Lymphoma (Including Adult T-cell Leukemia-Lymphoma)
2016.03.08 R&D PDF (47KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2016 through Collaborative Research and Grants
2016.03.02 Corporate PDF (66KB)
Daiichi Sankyo Addresses Erroneous Media Reports on Concurrent Positions Held by Outside Directors
2016.02.25 R&D PDF (59KB)
Daiichi Sankyo Announces Commencement of Clinical Trials in Japan for Duchenne Muscular Dystrophy Treatment
2016.02.24 Corporate PDF (32KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2016.02.24 Corporate PDF (94KB)
Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2016
2016.02.17 Corporate PDF (88KB)
Daiichi Sankyo Launches Once-Daily LIXIANAⓇ Sales Alliance in Europe
2016.02.10 R&D PDF (88KB)
Daiichi Sankyo Joint Development Product Designated Under “SAKIGAKE Designation System”
2016.02.09 Corporate PDF (64KB)
Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure
2016.02.02 R&D PDF (45KB)
Daiichi Sankyo to Expand Access to Clinical Trial Data
2016.01.28 CSR PDF (66KB)
Daiichi Sankyo Selected for RobecoSAM Industry Mover Sustainability Award 2016
2016.01.12 R&D PDF (20KB)
Daiichi Sankyo Announces Results of Phase 3 International Joint Trial (RApsody) of Investigational Etanercept Biosimilar
2016.01.08 Corporate PDF (85KB)
Daiichi Sankyo Announces Change in Corporate Officer’s Responsibilities

In order to view the PDF files, you need to have Adobe Reader 5.0 or later version installed.